A
Addex Therapeutics
Small-molecule drug development for neurological disorders
About Addex Therapeutics
Addex Therapeutics is a clinical-stage pharmaceutical company developing orally available small-molecule allosteric modulators for neurological disorders. Headquartered in Geneva, Switzerland, it was founded in 2002 by co-founders Vincent Mutel, Tim Dyer and Mark Epping-Jordan.
Its pipeline includes dipraglurant for post-stroke and traumatic brain injury recovery, alongside GABAB positive allosteric modulator programs for substance use disorder and chronic cough. Its proprietary clinical and preclinical drug candidates are developed both internally and through a partner.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2007
News
Open roles
Addex Therapeutics in the Geneva ecosystem
The Addex Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
Michael J. Fox Foundation for Parkinson's Research
National Institutes of Health
Wellcome Trust
Innosuisse
Series A10 investors entered at this stage
Index Ventures
Sofinnova Partners
Medicxi
TVM Capital Life Science
Techno Venture Management
PolyTechnos Venture PartnersVinci Capital
Renaissance
Initiative Capital
Bio*One Capital
Series B and later7 investors entered at this stage
SR One
Roche Venture Fund
Varuma
BVF Partners
NEA
Indivior
Armistice Capital
Source: Dealroom Talent Intelligence.
See Addex Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


